Mechanistic insights into the rational design of masked antibodies

References

• Khalil DN, Smith EL, Brentjens RJ, Wolchok JD. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol. 2016;13:273–16. doi:10.1038/nrclinonc.2016.25.
   PubMed Web of Science ®Google Scholar
• Zahavi D, Weiner L. Monoclonal antibodies in cancer therapy. Antibodies. 2020;9:34. doi:10.3390/antib9030034.
   Web of Science ®Google Scholar
• Kintzing JR, Filsinger Interrante MV, Cochran JR. Emerging strategies for developing next-generation protein therapeutics for cancer treatment. Trends Pharmacol Sci. 2016;37:993–1008. doi:10.1016/j.tips.2016.10.005.
   PubMed Web of Science ®Google Scholar
• Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJT. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov. 2010;9:325–38. doi:10.1038/nrd3003.
   PubMed Web of Science ®Google Scholar
• Polu KR, Lowman HB. Probody therapeutics for targeting antibodies to diseased tissue. Expert Opin Biol Ther. 2014;14:1049–53. doi:10.1517/14712598.2014.920814.
   PubMed Web of Science ®Google Scholar
• Kavanaugh WM. Antibody prodrugs for cancer. Expert Opin Biol Ther. 2020;20:163–71. doi:10.1080/14712598.2020.1699053.
   PubMed Web of Science ®Google Scholar
• Lin -W-W, Lu Y-C, Chuang C-H, Cheng T-L. Ab locks for improving the selectivity and safety of antibody drugs. J Biomed Sci. 2020;27:76. doi:10.1186/s12929-020-00652-z.
   PubMed Web of Science ®Google Scholar
• Desnoyers LR, Vasiljeva O, Richardson JH, Yang A, Menendez EEM, Liang TW, Wong C, Bessette PH, Kamath K, Moore SJ, et al. Tumor-specific activation of an EGFR-targeting probody enhances therapeutic index. Sci Transl Med. 2013;5:207ra144. doi:10.1126/scitranslmed.3006682.
   PubMed Web of Science ®Google Scholar
• Stroh M, Green M, Millard BL, Apgar JF, Burke JM, Garner W, Lu H, Lyman SK, Desnoyers LR, Richardson J, et al. Model‐informed drug development of the masked Anti‑PD‑L1 antibody CX‐072. Clin Pharmacol Ther. 2021;109:383–93. doi:10.1002/cpt.1985.
   PubMed Web of Science ®Google Scholar
• Erster O, Thomas JM, Hamzah J, Jabaiah AM, Getz JA, Schoep TD, Hall SS, Ruoslahti E, Daugherty PS. Site-Specific targeting of antibody activity in vivo mediated by disease-associated proteases. J Control Release. 2012;161:804–12. doi:10.1016/j.jconrel.2012.05.035.
   PubMed Web of Science ®Google Scholar
• Onuoha SC, Ferrari M, Sblattero D, Pitzalis C. Rational design of antirheumatic prodrugs specific for sites of inflammation. Arthritis Rheumatol. 2015;67:2661–72. doi:10.1002/art.39232.
   PubMed Web of Science ®Google Scholar
• Pai -C-CS, Simons DM, Lu X, Evans M, Wei J, Wang Y, Chen M, Huang J, Park C, Chang A, et al. Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity. J Clin Invest. 2018;129:349–63. doi:10.1172/JCI123391.
   PubMed Web of Science ®Google Scholar
• Geiger M, Stubenrauch K-G, Sam J, Richter WF, Jordan G, Eckmann J, Hage C, Nicolini V, Freimoser-Grundschober A, Ritter M, et al. Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody. Nat Commun. 2020;11:3196. doi:10.1038/s41467-020-16838-w.
   PubMed Web of Science ®Google Scholar
• Panchal A, Seto P, Wall R, Hillier BJ, Zhu Y, Krakow J, Datt A, Pongo E, Bagheri A, Chen T-HT, et al. COBRATM: a highly potent conditionally active T cell engager engineered for the treatment of solid tumors. MAbs. 2020;12:1792130. doi:10.1080/19420862.2020.1792130.
   PubMed Web of Science ®Google Scholar
• Kim H, Gaynor A, Chen W. Tunable modulation of antibody‐antigen interaction by protease cleavage of protein M. Biotechnol Bioeng. 2019;116:2834–42. doi:10.1002/bit.27111.
   PubMed Web of Science ®Google Scholar
• Trang VH, Zhang X, Yumul RC, Zeng W, Stone IJ, Wo SW, Dominguez MM, Cochran JH, Simmons JK, Ryan MC, et al. A coiled-coil masking domain for selective activation of therapeutic antibodies. Nat Biotechnol. 2019;37:761–65. doi:10.1038/s41587-019-0135-x.
   PubMed Web of Science ®Google Scholar
• Wouters SFA, Wijker E, Merkx M. Optical control of antibody activity by using photocleavable bivalent peptide–DNA locks. ChemBioChem. 2019;20:2463–66. doi:10.1002/cbic.201900241.
   PubMed Web of Science ®Google Scholar
• Engelen W, Zhu K, Subedi N, Idili A, Ricci F, Tel J, Merkx M. Programmable bivalent peptide–DNA locks for PH-based control of antibody activity. ACS Cent Sci. 2020;6:22–31. doi:10.1021/acscentsci.9b00964.
   PubMed Web of Science ®Google Scholar
• Janssen BMG, Lempens EHM, Olijve LLC, Voets IK, van Dongen JLJ, de Greef TFA, Merkx M. Reversible blocking of antibodies using bivalent peptide–DNA conjugates allows protease-activatable targeting. Chem Sci. 2013;4:1442. doi:10.1039/c3sc22033h.
   Web of Science ®Google Scholar
• Chen I-J, Chuang C-H, Hsieh Y-C, Lu Y-C, Lin -W-W, Huang -C-C, Cheng T-C, Cheng Y-A, Cheng K-W, Wang Y-T, et al. Selective antibody activation through protease-activated pro-antibodies that mask binding sites with inhibitory domains. Sci Rep. 2017;7:11587. doi:10.1038/s41598-017-11886-7.
   PubMed Web of Science ®Google Scholar
• Lucchi R, Bentanachs J, Oller-Salvia B. The masking game: design of activatable antibodies and mimetics for selective therapeutics and cell control. ACS Cent Sci. 2021;7:724–38. doi:10.1021/acscentsci.0c01448.
   PubMed Web of Science ®Google Scholar
• Bleuez C, Koch WF, Urbach C, Hollfelder F, Jermutus L. Exploiting protease activation for therapy. Drug Discov Today. 2022;27:1743–54. doi:10.1016/j.drudis.2022.03.011.
   PubMed Web of Science ®Google Scholar
• Gunnoo SB, Finney HM, Baker TS, Lawson AD, Anthony DC, Davis BG. Creation of a gated antibody as a conditionally functional synthetic protein. Nat Commun. 2014;5:4388. doi:10.1038/ncomms5388.
   PubMed Web of Science ®Google Scholar
• Donaldson JM, Kari C, Fragoso RC, Rodeck U, Williams JC. Design and development of masked therapeutic antibodies to limit off-target effects: application to Anti-EGFR antibodies. Cancer Biol Ther. 2009;8:2147–52. doi:10.4161/cbt.8.22.9765.
   PubMed Web of Science ®Google Scholar
• Lu Y-C, Chuang C-H, Chuang K-H, Chen I-J, Huang B-C, Lee W-H, Wang H-E, Li -J-J, Cheng Y-A, Cheng K-W, et al. Specific activation of pro-infliximab enhances selectivity and safety of rheumatoid arthritis therapy. PLOS Biol. 2019;17:e3000286. doi:10.1371/journal.pbio.3000286.
   PubMed Web of Science ®Google Scholar
• Metz S, Panke C, Haas AK, Schanzer J, Lau W, Croasdale R, Hoffmann E, Schneider B, Auer J, Gassner C, et al. Bispecific antibody derivatives with restricted binding functionalities that are activated by proteolytic processing. Protein Eng Des Sel. 2012;25:571–80. doi:10.1093/protein/gzs064.
   PubMed Web of Science ®Google Scholar
• Ngambenjawong C, Sylvestre M, Gustafson HH, Pineda JMB, Pun SH. Reversibly switchable, PH-dependent peptide ligand binding via 3,5-Diiodotyrosine substitutions. ACS Chem Biol. 2018;13:995–1002. doi:10.1021/acschembio.8b00171.
   PubMed Web of Science ®Google Scholar
• Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer. 2007;7:332–44. doi:10.1038/nrc2106.
   PubMed Web of Science ®Google Scholar
• Guglin M, Cutro R, Mishkin JD. Trastuzumab-Induced cardiomyopathy. J Card Fail. 2008;14:437–44. doi:10.1016/j.cardfail.2008.02.002.
   PubMed Web of Science ®Google Scholar
• Coelho M, Gauthier P, Pugnière M, Roquet F, Pèlegrin A, Navarro-Teulon I. Isolation and characterisation of a human anti-idiotypic ScFv used as a surrogate tumour antigen to elicit an Anti-HER-2/Neu humoral response in mice. Br J Cancer. 2004;90:2032–41. doi:10.1038/sj.bjc.6601825.
   PubMed Web of Science ®Google Scholar
• Alvarez-Rueda N, Ladjemi MZ, Béhar G, Corgnac S, Pugnière M, Roquet F, Bascoul-Mollevi C, Baty D, Pèlegrin A, Navarro-Teulon I. A llama single domain anti-idiotypic antibody mimicking HER2 as a Vaccine: immunogenicity and efficacy. Vaccine. 2009;27:4826–33. doi:10.1016/j.vaccine.2009.05.067.
   PubMed Web of Science ®Google Scholar
• Hsu EJ, Cao X, Moon B, Bae J, Sun Z, Liu Z, Y-X F. A cytokine receptor-masked IL2 prodrug selectively activates tumor-infiltrating lymphocytes for potent antitumor therapy. Nat Commun. 2021;12:2768. doi:10.1038/s41467-021-22980-w.
   PubMed Web of Science ®Google Scholar
• Skrombolas D, Sullivan M, Frelinger JG. Development of an Interleukin-12 fusion protein that is activated by cleavage with matrix metalloproteinase 9. J Interf Cytokine Res. 2019;39:233–45. doi:10.1089/jir.2018.0129.
   PubMed Web of Science ®Google Scholar
• Guo J, Liang Y, Xue D, Shen J, Cai Y, Zhu J, Fu Y-X, Peng H. Tumor-Conditional IL-15 pro-Cytokine reactivates anti-tumor immunity with limited toxicity. Cell Res. 2021;31:1190–98. doi:10.1038/s41422-021-00543-4.
   PubMed Web of Science ®Google Scholar
• Ravn P, Madhurantakam C, Kunze S, Matthews E, Priest C, O’Brien S, Collinson A, Papworth M, Fritsch-Fredin M, Jermutus L, et al. Structural and pharmacological characterization of novel potent and selective monoclonal antibody antagonists of glucose-dependent insulinotropic polypeptide receptor. J Biol Chem. 2013;288:19760–72. doi:10.1074/jbc.M112.426288.
   PubMed Web of Science ®Google Scholar
• Krishnamurthy VM, Semetey V, Bracher PJ, Shen N, Whitesides GM. Dependence of effective molarity on linker length for an intramolecular protein−ligand system. Journal of the American Chemical Society. 2007;129:1312–20. doi:10.1021/ja066780e.
   PubMed Web of Science ®Google Scholar
• Ram S, Kim D, Ober RJ, Ward ES. The level of HER2 expression is a predictor of antibody-HER2 trafficking behavior in cancer cells. MAbs. 2014;6:1211–19. doi:10.4161/mabs.29865.
   PubMed Web of Science ®Google Scholar
• Dobson CL, Devine PWA, Phillips JJ, Higazi DR, Lloyd C, Popovic B, Arnold J, Buchanan A, Lewis A, Goodman J, et al. Engineering the surface properties of a human monoclonal antibody prevents self-association and rapid clearance in vivo. Sci Rep. 2016;6:38644. doi:10.1038/srep38644.
   PubMed Web of Science ®Google Scholar
• Kim M, Sun Z-YJ, Rand KD, Shi X, Song L, Cheng Y, Fahmy AF, Majumdar S, Ofek G, Yang Y, et al. Antibody mechanics on a membrane-bound HIV segment essential for GP41-targeted viral neutralization. Nat Struct Mol Biol. 2011;18:1235–43. doi:10.1038/nsmb.2154.
   PubMed Web of Science ®Google Scholar
• Cho H-S, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW, Leahy DJ. Structure of the extracellular region of HER2 alone and in complex with the herceptin fab. Nature. 2003;421:756–60. doi:10.1038/nature01392.
   PubMed Web of Science ®Google Scholar
• Krissinel E, Henrick K. Inference of macromolecular assemblies from crystalline State. J Mol Biol. 2007;372:774–97. doi:10.1016/j.jmb.2007.05.022.
   PubMed Web of Science ®Google Scholar
• Daramola O, Stevenson J, Dean G, Hatton D, Pettman G, Holmes W, Field R. A High-Yielding CHO transient system: coexpression of genes encoding EBNA-1 and GS enhances transient protein expression. Biotechnol Prog. 2014;30:132–41. doi:10.1002/btpr.1809.
   PubMed Web of Science ®Google Scholar
• Webster CI, Hatcher J, Burrell M, Thom G, Thornton P, Gurrell I, Chessell I. Enhanced delivery of IL-1 receptor antagonist to the central nervous system as a novel anti-transferrin receptor-IL-1RA fusion reverses neuropathic mechanical hypersensitivity. Pain. 2017;158:660–68. doi:10.1097/j.pain.0000000000000810.
   PubMed Web of Science ®Google Scholar
• Schiettecatte J, Anckaert E, and Smitz J. Interferences in immunoassays. In: Chiu NHL, Christopoulos TK, editors. Advances in Immunoassay Technology. Rijeka: InTech; 2012. p. 45–62.
   Google Scholar
• Tate J, Ward G, Hansel TT, Kropshofer H, Singer T, Mitchell JA. Interferences in Immunoassay. Clin Biochem Rev. 2004;25:105–20.
   PubMedGoogle Scholar
• Fernando SA, Wilson GS. Studies of the ‘Hook’ effect in the one-step sandwich immunoassay. J Immunol Methods. 1992;151:47–66. doi:10.1016/0022-1759(92)90104-2.
   PubMed Web of Science ®Google Scholar
• Vonrhein C, Flensburg C, Keller P, Sharff A, Smart O, Paciorek W, Womack T, Bricogne G. Data processing and analysis with the AutoPROC Toolbox. Acta Crystallogr Sect D Biol Crystallogr. 2011;67:293–302. IUCr. doi:10.1107/S0907444911007773.
   PubMedGoogle Scholar
• McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ. Phaser crystallographic software. J Appl Crystallogr. 2007;40:658–74. IUCr. doi:10.1107/S0021889807021206.
   PubMed Web of Science ®Google Scholar
• Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of Coot. Acta Crystallogr Sect D Biol Crystallogr. 2010;66:486–501. IUCr. doi:10.1107/S0907444910007493.
   PubMed Web of Science ®Google Scholar
• Murshudov GN, Skubák P, Lebedev AA, Pannu NS, Steiner RA, Nicholls RA, Winn MD, Long F, Vagin AA. REFMAC 5 for the refinement of macromolecular crystal structures. Acta Crystallogr Sect D Biol Crystallogr. 2011;67:355–67. IUCr. doi:10.1107/S0907444911001314.
   PubMed Web of Science ®Google Scholar
• Bricogne G, Blanc E, Brandl M, Flensburg C, Keller P, Paciorek W, Roversi P, Smart OS, Vonrhein C, Womack TO. BUSTER Version 2.8.0. Cambridge, United Kindgom Glob Phasing Ltd. 2009
   Google Scholar